By browsing our site you accept the installation and use cookies on your computer. Know more

Menu Logo Principal

Home

Unité de Virologie et Immunologie Moléculaires

Publications

New Insights into Structural Disorder in Human Respiratory Syncytial Virus Phosphoprotein and Implications for Binding of Protein Partners. Pereira N, Cardone C, Lassoued S, Galloux M, Fix J, Assrir N, Lescop E, Bontems F, Eléouët JF, Sizun C. J Biol Chem. 2016 Dec 28. pii: jbc.M116.765958. doi: 10.1074/jbc.M116.765958.

Non-invasive epicutaneous vaccine against Respiratory Syncytial Virus: Preclinical proof of concept. Hervé PL, Descamps D, Deloizy C, Dhelft V, Laubreton D, Bouguyon E, Boukadiri A, Dubuquoy C, Larcher T, Benhamou PH, Eléouët JF, Bertho N, Mondoulet L, Riffault S. J Control Release. 2016 Dec 10;243:146-159. doi: 10.1016/j.jconrel.2016.10.003.

RSV N-nanorings fused to palivizumab-targeted neutralizing epitope as a nanoparticle RSV vaccine. Hervé PL, Deloizy C, Descamps D, Rameix-Welti MA, Fix J, McLellan JS, Eléouët JF, Riffault S. Nanomedicine. 2016 Aug 20. pii: S1549-9634(16)30114-9. doi: 10.1016/j.nano.2016.08.006.

Targeting human respiratory syncytial virus transcription anti-termination factor M2-1 to inhibit in vivo viral replication. Bailly B, Richard CA, Sharma G, Wang L, Johansen L, Cao J, Pendharkar V, Sharma DC, Galloux M, Wang Y, Cui R, Zou G, Guillon P, von Itzstein M, Eléouët JF, Altmeyer R. Sci Rep. 2016 May 19;6:25806. doi: 10.1038/srep25806.

A druggable pocket at the nucleocapsid/phosphoprotein interaction site of the human respiratory syncytial virus. Ouizougun-Oubari M, Pereira N, Tarus B, Galloux M, Lassoued S, Fix J, Tortorici MA, Hoos S, Baron B, England P, Desmaële D, Couvreur P, Bontems F, Rey FA, Eléouët JF, Sizun C, Slama-Schwok A, Duquerroy S. J Virol. 2015 Aug 5. pii: JVI.01612-15

A bovine respiratory syncytial virus model with high clinical expression in calves with specific passive immunity. Blodörn K, Hägglund S, Gavier-Widen D, Eléouët JF, Riffault S, Pringle J, Taylor G, Valarcher JF. BMC Vet Res. 2015 Mar 25;11:76. doi: 10.1186/s12917-015-0389-6.

Fine mapping and characterization of the L-polymerase-binding domain of the respiratory syncytial virus phosphoprotein. Sourimant J, Rameix-Welti MA, Gaillard AL, Chevret D, Galloux M, Gault E, Eléouët JF. J Virol. 2015 Apr;89(8):4421-33. doi: 10.1128/JVI.03619-14. Epub 2015 Feb 4. PMID: 25653447

Identification and characterization of the binding site of the respiratory syncytial virus phosphoprotein to RNA-free nucleoprotein. Galloux M, Gabiane G, Sourimant J, Richard CA, England P, Moudjou M, Aumont-Nicaise M, Fix J, Rameix-Welti MA, Eléouët JF. J Virol. 2015 Apr;89(7):3484-96. doi: 10.1128/JVI.03666-14. Epub 2015 Jan 7. PMID: 25568210

Interactome analysis of the human respiratory syncytial virus RNA polymerase complex identifies protein chaperones as important co-factors that promote L protein stability and RNA synthesis. Munday DC, Wu W, Smith N, Fix J, Noton SL, Galloux M, Touzelet O, Armstrong SD, Dawson JM, Aljabr W, Easton AJ, Rameix-Welti MA, de Oliveira AP, Simabuco F, Ventura AM, Hughes DJ, Barr JN, Fearns R, Digard P, Eléouët JF, Hiscox JA. J Virol. 2014 Oct 29.

Visualizing the replication of respiratory syncytial virus in cells and in living mice. Rameix-Welti MA, Le Goffic R, Hervé PL, Sourimant J, Rémot A, Riffault S, Yu Q, Galloux M, Gault E, Eléouët JF. Nat Commun. 2014 Oct 3;5:5104

Vaccine safety and efficacy evaluation of a recombinant bovine respiratory syncytial virus (BRSV) with deletion of the SH gene and subunit vaccines based on recombinant human RSV proteins: N-nanorings, P and M2-1, in calves with maternal antibodies. Blodörn K, Hägglund S, Fix J, Dubuquoy C, Makabi-Panzu B, Thom M, Karlsson P, Roque JL, Karlstam E, Pringle J, Eléouët JF, Riffault S, Taylor G, Valarcher JF. PLoS One. 2014 Jun 19;9(6):e100392

Characterization of an experimental vaccine for bovine respiratory syncytial virus. Hägglund S, Hu K, Blodörn K, Makabi-Panzu B, Gaillard AL, Ellencrona K, Chevret D, Hellman L, Bengtsson KL, Riffault S, Taylor G, Valarcher JF, Eléouët JF. Clin Vaccine Immunol. 2014 Jul;21(7):997-1004

Crystal structure of the essential transcription antiterminator M2-1 protein of human respiratory syncytial virus and implications of its phosphorylation. Tanner SJ, Ariza A, Richard CA, Kyle HF, Dods RL, Blondot ML, Wu W, Trincão J, Trinh CH, Hiscox JA, Carroll MW, Silman NJ, Eléouët JF, Edwards TA, Barr JN. Proc Natl Acad Sci U S A. 2014 Jan 28;111(4):1580-5.

A novel subnucleocapsid nanoplatform for mucosal vaccination against influenza virus that targets the ectodomain of matrix protein 2. Hervé PL, Raliou M, Bourdieu C, Dubuquoy C, Petit-Camurdan A, Bertho N, Eléouët JF, Chevalier C, Riffault S. J Virol. 2014 Jan;88(1):325-38.

The respiratory syncytial virus nucleoprotein-RNA complex forms a left-handed helical nucleocapsid. Bakker SE, Duquerroy S, Galloux M, Loney C, Conner E, Eléouët JF, Rey FA, Bhella D. J Gen Virol. 2013 Aug;94(Pt 8):1734-8.

Structure and functional analysis of the RNA- and viral phosphoprotein-binding domain of respiratory syncytial virus M2-1 protein. Blondot ML, Dubosclard V, Fix J, Lassoued S, Aumont-Nicaise M, Bontems F, Eléouët JF, Sizun C. PLoS Pathog. 2012;8(5):e1002734

Characterization of a viral phosphoprotein binding site on the surface of the respiratory syncytial nucleoprotein. Galloux M, Tarus B, Blazevic I, Fix J, Duquerroy S, Eléouët JF. J Virol. 2012 Aug;86(16):8375-87

Recent publications: